Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus Infections | 9 | 2024 | 200 | 4.510 |
Why?
|
| Respiratory Tract Infections | 10 | 2024 | 266 | 4.470 |
Why?
|
| Respiratory Syncytial Virus, Human | 6 | 2024 | 155 | 2.240 |
Why?
|
| Asthma | 2 | 2023 | 33 | 1.490 |
Why?
|
| Infant | 22 | 2025 | 2244 | 1.310 |
Why?
|
| Hospitalization | 7 | 2024 | 418 | 1.190 |
Why?
|
| Respiratory Function Tests | 2 | 2025 | 10 | 1.140 |
Why?
|
| Coinfection | 3 | 2024 | 276 | 1.130 |
Why?
|
| Feasibility Studies | 1 | 2025 | 101 | 0.920 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 253 | 0.870 |
Why?
|
| Child | 15 | 2024 | 2242 | 0.850 |
Why?
|
| Pneumonia | 6 | 2022 | 131 | 0.830 |
Why?
|
| Humans | 29 | 2025 | 14537 | 0.830 |
Why?
|
| Rural Population | 2 | 2025 | 654 | 0.830 |
Why?
|
| Child, Preschool | 15 | 2024 | 1748 | 0.810 |
Why?
|
| Vaccines | 1 | 2023 | 86 | 0.800 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 47 | 0.750 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2020 | 4 | 0.720 |
Why?
|
| Organizations, Nonprofit | 1 | 2019 | 1 | 0.660 |
Why?
|
| Sepsis | 1 | 2020 | 102 | 0.650 |
Why?
|
| Health Education | 1 | 2019 | 35 | 0.650 |
Why?
|
| Female | 16 | 2025 | 9103 | 0.580 |
Why?
|
| Infant, Newborn | 5 | 2025 | 1479 | 0.530 |
Why?
|
| Male | 14 | 2025 | 6754 | 0.490 |
Why?
|
| Respiratory Sounds | 3 | 2023 | 10 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 142 | 0.400 |
Why?
|
| South Africa | 15 | 2024 | 7596 | 0.400 |
Why?
|
| Paramyxoviridae Infections | 2 | 2023 | 27 | 0.390 |
Why?
|
| Metapneumovirus | 2 | 2023 | 30 | 0.390 |
Why?
|
| Case-Control Studies | 4 | 2023 | 480 | 0.320 |
Why?
|
| Child Health | 4 | 2022 | 77 | 0.310 |
Why?
|
| Pneumococcal Infections | 3 | 2023 | 299 | 0.300 |
Why?
|
| Pregnancy | 3 | 2023 | 1862 | 0.300 |
Why?
|
| Prospective Studies | 4 | 2024 | 1160 | 0.270 |
Why?
|
| Cohort Studies | 3 | 2025 | 967 | 0.260 |
Why?
|
| Empyema, Pleural | 2 | 2015 | 2 | 0.260 |
Why?
|
| Bangladesh | 1 | 2025 | 17 | 0.240 |
Why?
|
| Kartagener Syndrome | 1 | 2024 | 1 | 0.240 |
Why?
|
| Auscultation | 2 | 2022 | 6 | 0.230 |
Why?
|
| European Union | 1 | 2023 | 3 | 0.230 |
Why?
|
| Palivizumab | 1 | 2023 | 10 | 0.230 |
Why?
|
| HIV-1 | 2 | 2023 | 1260 | 0.220 |
Why?
|
| United States | 1 | 2023 | 132 | 0.220 |
Why?
|
| Immunization, Passive | 1 | 2023 | 17 | 0.210 |
Why?
|
| Bronchiolitis | 1 | 2023 | 8 | 0.210 |
Why?
|
| Bronchiolitis, Viral | 1 | 2023 | 9 | 0.210 |
Why?
|
| Bronchopneumonia | 1 | 2023 | 11 | 0.210 |
Why?
|
| Disease Progression | 1 | 2023 | 154 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2023 | 54 | 0.210 |
Why?
|
| Prevalence | 3 | 2024 | 1192 | 0.200 |
Why?
|
| Stethoscopes | 1 | 2022 | 2 | 0.200 |
Why?
|
| Perches | 1 | 2022 | 3 | 0.200 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.190 |
Why?
|
| Africa | 2 | 2021 | 376 | 0.190 |
Why?
|
| Thorax | 1 | 2020 | 3 | 0.180 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2020 | 28 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 265 | 0.180 |
Why?
|
| Patient Selection | 1 | 2020 | 40 | 0.180 |
Why?
|
| Parturition | 1 | 2020 | 31 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2020 | 57 | 0.180 |
Why?
|
| Survival Rate | 1 | 2020 | 96 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2020 | 889 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.170 |
Why?
|
| Retrospective Studies | 2 | 2020 | 799 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 195 | 0.170 |
Why?
|
| Adolescent | 3 | 2021 | 2985 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 244 | 0.160 |
Why?
|
| Poverty | 1 | 2020 | 152 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2023 | 374 | 0.160 |
Why?
|
| Tuberculosis | 2 | 2015 | 543 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 43 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 127 | 0.150 |
Why?
|
| Streptococcus pneumoniae | 2 | 2017 | 336 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 34 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 2 | 2017 | 278 | 0.140 |
Why?
|
| Urban Population | 1 | 2019 | 257 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 551 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 1475 | 0.140 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 103 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2015 | 1 | 0.130 |
Why?
|
| Chest Tubes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 33 | 0.120 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 92 | 0.120 |
Why?
|
| HIV Infections | 4 | 2023 | 5097 | 0.120 |
Why?
|
| Calcitriol | 1 | 2014 | 6 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 6 | 0.120 |
Why?
|
| Zinc Sulfate | 1 | 2014 | 6 | 0.110 |
Why?
|
| Tuberculin Test | 1 | 2014 | 49 | 0.110 |
Why?
|
| Developing Countries | 3 | 2021 | 400 | 0.110 |
Why?
|
| Antitubercular Agents | 1 | 2015 | 322 | 0.100 |
Why?
|
| Hospitals | 2 | 2023 | 103 | 0.100 |
Why?
|
| Patient Acuity | 2 | 2021 | 18 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2021 | 81 | 0.090 |
Why?
|
| Logistic Models | 2 | 2021 | 254 | 0.090 |
Why?
|
| Genomics | 1 | 2024 | 109 | 0.050 |
Why?
|
| Phylogeny | 1 | 2024 | 231 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 10 | 0.050 |
Why?
|
| Binding Sites | 1 | 2023 | 43 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2023 | 179 | 0.050 |
Why?
|
| Lung | 1 | 2022 | 70 | 0.050 |
Why?
|
| Seizures | 1 | 2021 | 20 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 21 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2021 | 22 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 293 | 0.040 |
Why?
|
| Radiography | 1 | 2020 | 80 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 435 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 133 | 0.040 |
Why?
|
| Child Mortality | 1 | 2020 | 96 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 365 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 193 | 0.040 |
Why?
|
| Animals | 1 | 2022 | 1081 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 42 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2017 | 72 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 150 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 153 | 0.030 |
Why?
|
| Pleural Cavity | 1 | 2015 | 7 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 5 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 7 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 231 | 0.030 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2015 | 8 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 31 | 0.030 |
Why?
|
| Lopinavir | 1 | 2015 | 137 | 0.030 |
Why?
|
| Ritonavir | 1 | 2015 | 137 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2015 | 171 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 31 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 188 | 0.030 |
Why?
|
| Adult | 1 | 2024 | 5913 | 0.030 |
Why?
|
| Time Factors | 1 | 2014 | 507 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 472 | 0.030 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 324 | 0.020 |
Why?
|